2018 Opioid Induced Constipation (OIC) Drug Development- Pipeline Analysis Report

May 2018 | | ID: 2E4E9A00806EN
VPAResearch

Abstracts

With an estimated $600 million market value, the Opioid Induced Constipation (OIC) is one of the most common gastrointestinal conditions, presenting robust opportunities for development of treatment options. The condition is observed in patients who undergo opioid therapy and is characterized by lowered number of bowel movements and tough consistency. In addition to hard bowel moment, other symptoms of OIC include bloating and abdominal pain.

Over 15 companies and universities are focusing on developing treatment options for Opioid Induced Constipation (OIC).

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Opioid Induced Constipation (OIC) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Opioid Induced Constipation (OIC) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Opioid Induced Constipation (OIC) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 OPIOID INDUCED CONSTIPATION PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Opioid Induced Constipation Pipeline Snapshot
2.3 Opioid Induced Constipation Pipeline by Phase
2.4 Opioid Induced Constipation Pipeline by Company
2.5 Opioid Induced Constipation Pipeline by Mechanism of Action

3 OPIOID INDUCED CONSTIPATION- COMPANY WISE PIPELINE ANALYSIS

Algobate AG
Ironwood Pharmaceuticals
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Shionogi & Co Ltd
Synergy Pharmaceuticals Inc
Theravance Biopharma Inc

4 OPIOID INDUCED CONSTIPATION R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN OPIOID INDUCED CONSTIPATION PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Opioid Induced Constipation Pipeline by Phase, H1- 2018
Figure 2: Opioid Induced Constipation Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Opioid Induced Constipation Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Opioid Induced Constipation Pipeline by Phase, H1- 2018
Table 2: Opioid Induced Constipation Pipeline by Companies, H1- 2018
Table 3: Opioid Induced Constipation Pipeline by Mechanism of Action, H1- 2018
Table 4: Algobate AG Opioid Induced Constipation/OIC pipeline, May 2018
Table 5: Ironwood Pharmaceuticals Opioid Induced Constipation/OIC pipeline, May 2018
Table 6: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Opioid Induced Constipation/OIC pipeline, May 2018
Table 7: Shionogi & Co Ltd Opioid Induced Constipation/OIC pipeline, May 2018
Table 8: Synergy Pharmaceuticals Inc Opioid Induced Constipation/OIC pipeline, May 2018
Table 9: Theravance Biopharma Inc Opioid Induced Constipation/OIC pipeline, May 2018